Nurix to work with Roche on BTK degrader in pact worth up to $2.3B

Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B-cell malignancies.

lunedì 8 giugno 2026 New tab

89 words~1 min read

Arthur Sands, Nurix Therapeutics CEO

June 8, 2026 06:57 AM EDT

DealsR&D

Reynald Castaneda

Deputy Editor

Other newsrooms on this story

· 9 sources

· 9 sources

Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove…

biopharmadive.com3 mesi fa

(Bloomberg) -- Roche Holding AG agreed to pay Nurix Therapeutics Inc. as much as $2.3 billion for rights to an experimental…

swissinfo.ch3 mesi fa

Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Phase 3 plans for bexobrutideg.

benzinga.com3 mesi fa

Shares bounded off their 50-day line Monday after inking a deal with Roche for a BTK-degrading drug.

investors.com3 mesi fa

Roche pledges $700 million to join research on the drug bexobrutideg.

swissinfo.ch3 mesi fa

36氪获悉，隆基绿能公告，控股股东李振国将其原质押给国通信托的1.55亿股无限售流通股办理了解除质押手续，占其所持股份的14.52%。本次解除质押后，李振国累计质押公司股份2.1亿股，占其持股数量的19.68%。

36kr.com3 mesi fa